Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | YAP1 | P46937 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122818 | 0.95 | KRAS (0.75) | KRASGAAMAPTTXKJAK3 | |
| SCHEMBL20260214 | 0.90 | KRAS (0.61) | KRASGAAMAPTTXKJAK3 | |
| SCHEMBL15337874 | 0.90 | KRAS (0.82) | KRASGAASCDMELKEGLN1 | |
| SCHEMBL16122615 | 0.88 | KRAS (0.61) | KRASGAAMAPTTXKJAK3 | |
| SCHEMBL20240049 | 0.87 | KRAS (0.74) | KRASSCD | |
| SCHEMBL16117834 | 0.87 | KRAS (0.74) | KRASSCD | |
| SCHEMBL20381549 | 0.86 | KRAS (0.62) | KRASGAAMAPTTXKJAK3 | |
| SCHEMBL16122742 | 0.86 | KRAS (0.71) | KRASGAASCDMELK | |
| SCHEMBL16122674 | 0.86 | KRAS (0.71) | KRASGAASCDMELKEGLN1 | |
| SCHEMBL16122759 | 0.86 | KRAS (0.91) | KRASGAASCDMELKEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MAPT 4316/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MAPT 4316/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MAPT 4316/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MAPT 4316/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | KRAS 1/4885GAA 1747/4885MAPT 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.